ACBT (4148) reported revenue of NT$323 million for Oct 2026, -2.0% year on year and -12.1% from the previous month. Revenue for Jan–Oct 2026 was NT$2.93 billion (+19.7% year on year).
In Oct 2026, it ranked No. 31 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$323 million | -2.0% | -12.1% |
| Sep 2026 | NT$367.4 million | +5.3% | -0.3% |
| Aug 2026 | NT$368.4 million | +51.9% | +4.4% |
| Jul 2026 | NT$353 million | +39.3% | +1.8% |
| Jun 2026 | NT$346.7 million | +31.5% | +25.5% |
| May 2026 | NT$276.2 million | +21.8% | -23.7% |
| Apr 2026 | NT$362 million | +55.0% | +69.4% |
| Mar 2026 | NT$213.7 million | -18.6% | +22.8% |
| Feb 2026 | NT$174.1 million | +10.8% | +20.0% |
| Jan 2026 | NT$145.1 million | +12.2% | -46.7% |
| Dec 2025 | NT$272.2 million | +12.5% | +16.5% |
| Nov 2025 | NT$233.6 million | +6.3% | -29.1% |
| Oct 2025 | NT$329.7 million | +29.0% | -5.5% |
| Sep 2025 | NT$348.9 million | +34.0% | +43.9% |
| Aug 2025 | NT$242.4 million | -14.3% | -4.3% |
| Jul 2025 | NT$253.3 million | +16.7% | -3.9% |
| Jun 2025 | NT$263.6 million | +66.8% | +16.2% |
| May 2025 | NT$226.8 million | +21.4% | -2.9% |
| Apr 2025 | NT$233.5 million | +76.2% | -11.1% |
| Mar 2025 | NT$262.6 million | +46.7% | +67.2% |
| Feb 2025 | NT$157.1 million | -13.7% | +21.5% |
| Jan 2025 | NT$129.3 million | -19.9% | -46.6% |
| Dec 2024 | NT$241.9 million | +60.6% | +10.0% |
| Nov 2024 | NT$219.9 million | -3.3% | -14.0% |
| Oct 2024 | NT$255.6 million | +34.7% | -1.8% |
Jan–Oct 2026 cumulative: NT$2.93 billion (+19.7% YoY)
Other Biotech & Medical companies
Compare with peers: ACBT vs PEC / ACBT vs Lotus Pharm / ACBT vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16